Page 79 - NobleCon20-Book-Project

GeoVax Labs, Inc.

SELECTED FINANCIAL ITEMS GOVX

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue NA NA 0.30 2.79 3.09
Gross Profit (6.23) (4.43) (3.98) 2.79 (11.85)
Gross Margin NM NM -1322% 100% -383%
EBIT (7.69) (5.88) (5.06) (5.85) (24.49)
EBIT Margin NM NM -1684% -210% -793%
Net Income to Common Shareholders (7.59) (5.85) (5.06) (5.82) (24.32)
Net Margin NM NM -1684% -208% -787%

Balance Sheet Key Items
Total Assets 9.28 3.36 4.10 11.11 11.11
Cash & Short Term Investments 6.45 0.77 1.56 8.59 8.59
% of Assets 70% 23% 38% 77% 77%
Current Assets -Total 7.89 2.86 3.84 10.87 10.87
% of Assets 85% 85% 94% 98% 98%
Total Liabilities 3.52 3.30 6.40 2.61 2.61
% of Assets 38% 98% 156% 23% 23%
Current Liabilities - Total 3.52 3.30 6.40 2.61 2.61
% of Assets 38% 98% 156% 23% 23%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 5.76 0.05 (2.31) 8.50 8.50
% of Assets 62% 2% -56% 77% 77%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (10.28) (5.68) (1.94) (9.30) (27.20)
Net Cash Flow - Investing (0.02) NA NA (0.02) (0.04)
Net Cash Flow - Financing 4.06 NA 2.73 16.35 23.14

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference